Virax Sets Nov 27 Vote on 1-for-4 Reverse Split and 4x Authorized Share Increase
VRAX sits 19% above its 52-week low of $0.503 on light trading volume (0.1× avg).
Summary
Virax shareholders will vote November 27 on a 1-for-4 reverse split effective December 14, 2026 and an increase in authorized capital to 500 million shares — a Nasdaq minimum-bid defense paired with a large new pool of shares to issue.
Key Events · Corporate Governance and Compliance · VRAX
-
1-for-4 Reverse Split Up for Vote
Shareholders vote November 27, 2026 on consolidating every 4 ordinary shares of US$0.025 par into one share of US$0.10 par, effective December 14, 2026 or a later date accepted by Nasdaq.
-
Authorized Shares to Quadruple
Authorized capital would rise from US$12,500,000 divided into 125,000,000 shares of US$0.10 par to US$50,000,000 divided into 500,000,000 shares, creating 375,000,000 new authorized shares for financing and business development.
-
No Nasdaq Cure Period Remaining
Because a 25-for-1 consolidation was already effected June 26, 2026, a closing bid below $1.00 for 30 consecutive business days would make the company ineligible for any compliance period and trigger a Staff Delisting Determination.
-
Charter Rewrite Requires Two-Thirds
Adopting the Fifth Amended and Restated Memorandum and Articles is a special resolution needing two-thirds of votes cast; the split and capital increase need only a simple majority.
Analysis · VRAX · Life Sciences
The vote matters because the split is a defensive move: with the stock at $0.60, below Nasdaq's $1.00 minimum bid, and a 25-for-1 consolidation already effected on June 26, 2026, a 30-day sub-$1.00 stretch would leave no compliance period at all — Nasdaq would issue a Staff Delisting Determination. Shareholders are being asked to approve a 1-for-4 consolidation effective December 14, 2026, and then immediately quadruple authorized capital to 500 million shares of US$0.10 par. That capital increase is the other half of the story: it hands management roughly 375 million new authorized shares to issue for 'basic financing needs' and business development, on top of an ATM with about $2.07 million of remaining capacity. Existing holders therefore face both a mechanical share-count reduction and a much larger pool of potential future dilution.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VRAX was trading at $0.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $823.9K. The 52-week trading range was $0.50 to $21.75. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.